Trial report in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Julie Ann KempGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói 24033-900, RJ, Brazil.ORCID 0000-0001-6739-8832
Marianna MendonçaGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói 24033-900, RJ, Brazil.
Paloma ChrispimGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói 24033-900, RJ, Brazil.
Marcia RibeiroGraduate Program in Biological Sciences-Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-941, RJ, Brazil.ORCID 0000-0002-4957-3630
Isadora BrittoGraduate Program in Biological Sciences-Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-941, RJ, Brazil.ORCID 0009-0009-0737-6127
Karen S Coutinho-WolinoGraduate Program in Biological Sciences-Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-941, RJ, Brazil.ORCID 0000-0002-2489-1237
Marcelo Ribeiro-AlvesHIV/AIDS Clinical Research Center, Evandro Chagas National Institute of Infectious Diseases (INI/Fiocruz), Rio de Janeiro 21040-360, RJ, Brazil.ORCID 0000-0002-8663-3364
Lia S NakaoBasic Pathology Department, Federal University of Paraná (UFPR), Curitiba 81531-980, PR, Brazil.ORCID 0000-0001-9647-6350
Fernanda KussiBasic Pathology Department, Federal University of Paraná (UFPR), Curitiba 81531-980, PR, Brazil.ORCID 0000-0001-7889-2748
Eduardo B CoelhoInternal Medicine Department, Ribeirão Preto Medical School, University of São Paulo (USP), São Paulo 14048-900, SP, Brazil.ORCID 0000-0003-3491-3396
Andresa A BerrettaResearch, Development & Innovation Department, Apis Flora Indl. Coml. Ltd, Ribeirão Preto 14020-670, SP, Brazil.ORCID 0000-0001-5719-1301
Denise MafraGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói 24033-900, RJ, Brazil.ORCID 0000-0001-6752-6056
Ludmila CardozoGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Niterói 24033-900, RJ, Brazil.
Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), 200162/2020-9, E-26/202.524/2019 and E-26/200.284/2023.
6 · The paper itself
Abstract
backgroundReducing cardiovascular risk markers is an essential target in chronic kidney disease (CKD). Thus, this study aimed to evaluate the effect of royal jelly plus green propolis supplementation on cardiovascular disease (CVD) risk factors in patients with CKD undergoing hemodialysis (HD).
methodsThis randomized, double-blind, placebo-controlled trial involved HD patients allocated to receive either royal jelly plus green propolis EPP-AF
resultsA total of 38 HD patients completed the 2-month supplementation study, with 19 patients in each group. After 2 months, the treated group showed a significant reduction in plasma levels of IL-6 (0.78 to 0.63 pg/mL,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Apitherapy with Royal Jelly and Green Propolis EPP-AF · full record | Socratic